[EN] ACYCLIC CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS [FR] CYANOÉTHYLPYRAZOLO PYRIDONES ACYCLIQUES EN TANT QU'INHIBITEURS DE JANUS KINASE
Nucleophilic Trifluoromethylation of Imines under Acidic Conditions
作者:Vitalij V. Levin、Alexander D. Dilman、Pavel A. Belyakov、Marina I. Struchkova、Vladimir A. Tartakovsky
DOI:10.1002/ejoc.200800820
日期:2008.11
A general method for the trifluoromethylation of imines by using Me3SiCF3 under acidic conditions is described. The reaction is promoted by hydrofluoric acid generated in situ from KHF2 and either TFA or TfOH. A new chemoselectivity pattern was achieved, as the C=N bond was found to be more reactivate than the carbonyl group. The trifluoromethylation reaction is believed to proceed by concerted transfer
An easy synthesis of α-trifluoromethyl-amines from aldehydes or ketones using the Ruppert-Prakash reagent
作者:Dmytro S. Radchenko、Oleg M. Michurin、Anton V. Chernykh、Oleg Lukin、Pavel K. Mykhailiuk
DOI:10.1016/j.tetlet.2013.01.132
日期:2013.4
A small library of structurally diverse primary amines bearing a geminal CF3 group was synthesized on a preparative scale. The synthesis starts with an aldehyde or ketone that reacts with benzylamine yielding the corresponding imine. The latter is then trifluoromethylated with Me3SiCF3 under acidic conditions to give a benzylalkylamine. In the last step the Pd-mediated hydrogenation of the benzylalkylamines
ACYCLIC CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS
申请人:DINSMORE Christopher
公开号:US20160272634A1
公开(公告)日:2016-09-22
The instant invention provides compounds of formula I which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.
Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors
申请人:Merck Sharp & Dohme Corp.
公开号:US10059705B2
公开(公告)日:2018-08-28
The instant invention provides compounds of formula I which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.
本发明提供的式 I 化合物是 JAK 抑制剂,因此可用于治疗 JAK 介导的疾病,如类风湿性关节炎、哮喘、慢性阻塞性肺病和癌症。